Posted inNews and Updates
EU Biotech Act: EMA Prepares for Major Regulatory Shifts
The EMA is adjusting its regulatory framework to align with the new EU Biotech Act, aiming to accelerate the approval of innovative biological therapies.
Posted inNews and Updates
Lilly’s New JAK Inhibitor Shows Promise in Early Data
Eli Lilly reports positive early-stage clinical results for its latest JAK inhibitor, signaling a potential breakthrough in treating inflammatory diseases.
Posted inNews and Updates
New Pancreatic Cancer Drug Strategy Significantly Extends Life
A new targeted drug strategy is showing potential to double survival rates for pancreatic cancer patients, marking a major breakthrough in oncology care.
Posted inNews and Updates
EU Clinical Trial Transparency: Data Reporting Gaps Found
New analysis reveals major reporting gaps in EU clinical trials, threatening medical transparency and patient safety. Read the implications for researchers.
Posted inNews and Updates
Masitinib Shows Survival Benefits in ALS Clinical Trial
New trial data suggests the tyrosine kinase inhibitor masitinib may improve five-year survival rates in ALS patients by targeting neuroinflammation.
Posted inNews and Updates
FDA Clears XBiotech to Resume Rheumatology Clinical Trial
The FDA has lifted a clinical hold on XBiotech's trial for axial spondyloarthritis. Learn how this move impacts the future of rheumatology drug development.
Posted inNews and Updates
XBiotech Launches Phase II Trial for Axial Spondyloarthritis
XBiotech has launched a Phase II trial for Vilamakitug, a novel IL-1α inhibitor aimed at treating patients with active axial spondyloarthritis.
Posted inNews and Updates
First Patient Dosed in Breakthrough Huntington’s Stem Cell Trial
A groundbreaking clinical trial has begun testing neural stem cell therapy as a potential treatment to repair brain damage in Huntington’s disease patients.
Posted inNews and Updates
Novo Nordisk Confirms Data Breach: Clinical Trial Risks
Novo Nordisk reports a major data breach affecting clinical trial files. Learn about the security risks and the impact on patient data protection.
Posted inNews and Updates
Tafasitamab Combo Shows Promise in Phase III FrontMIND Trial
Explore new Phase III results for tafasitamab in treating DLBCL. Learn how this combination therapy aims to improve progression-free survival in patients.